Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
Tiziano Barbui,Alessandro Maria Vannucchi,Valerio De Stefano,Alessandra Carobbio,Arianna Ghirardi,Greta Carioli,Arianna Masciulli,Elena Rossi,Fabio Ciceri,Massimiliano Bonifacio,Alessandra Iurlo,Francesca Palandri,Giulia Benevolo,Fabrizio Pane,Alessandra Ricco,Giuseppe Carli,Marianna Caramella,Davide Rapezzi,Caterina Musolino,Sergio Siragusa,Elisa Rumi,Andrea Patriarca,Nicola Cascavilla,Barbara Mora,Emma Cacciola,Carmela Mannarelli,Giuseppe Gaetano Loscocco,Paola Guglielmelli,Francesca Gesullo,Silvia Betti,Francesca Lunghi,Luigi Scaffidi,Cristina Bucelli,Nicola Vianelli,Marta Bellini,Maria Chiara Finazzi,Gianni Tognoni,Alessandro Rambaldi
DOI: https://doi.org/10.1056/EVIDoa2200335
Abstract:BACKGROUND: Whether phlebotomy alone can adequately maintain target hematocrit in patients with low-risk polycythemia vera (PV) remains elusive. METHODS: In a phase 2 open-label randomized trial, we compared ropeginterferon alfa-2b (ropeg; 100 μg every 2 weeks) with phlebotomy only regarding maintenance of a median hematocrit level (≤45%) over 12 months in the absence of progressive disease (primary end point). In follow-up, crossover to the alternative treatment group was allowed if the primary end point was not met. RESULTS: In total, 127 patients were enrolled (ropeg: n=64; standard group: n=63). The primary end point was met in 81% and 51% in the ropeg and standard groups, respectively. Responders continued the assigned treatment until month 24 and maintained response in 83% and 59%, respectively (P=0.02). Ropeg responders less frequently experienced moderate/severe symptoms (33% vs. 67% in the standard group) and palpable splenomegaly (14% vs. 37%) and showed normalization of ferritin levels and blood counts. Nonresponders at 12 months crossed over to the standard (n=9) or ropeg (n=23) group; in patients switched to ropeg only, 7 of 23 met the response criteria in 12 months, and phlebotomy need was high (4.7 per patient per year). Discontinuation because of adverse events occurred in seven patients treated with ropeg. CONCLUSIONS: In this 24-month trial, ropeg was superior to phlebotomy alone in maintaining hematocrit on target. No dose-limiting side effects or toxicities were noted; 9.2% of patients on ropeg and no patients on standard treatment developed neutropenia. (Funded by AOP Health and others; ClinicalTrials.gov number, NCT03003325.)